This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
Active as of 2023-12-17 |
<Citation xmlns="http://hl7.org/fhir">
<id value="179631"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2023-11-26T22:35:32.731Z"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Citation</b><a name="179631"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource Citation "179631" Version "1" Updated "2023-11-26 22:35:32+0000" </p></div><p><b>StructureDefinition Work Group</b>: cds</p><p><b>url</b>: <code>https://fevir.net/resources/Citation/179631</code></p><p><b>identifier</b>: FEvIR Object Identifier: 179631, id: 19029421</p><p><b>version</b>: 1.0.0-ballot</p><p><b>title</b>: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p><p><b>status</b>: active</p><p><b>date</b>: 2023-12-17 16:55:23+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td>FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')</td><td>Medline Base <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#medline-base)</span></td></tr></table><p><b>jurisdiction</b>: World <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (m49.htm#001)</span></p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>approvalDate</b>: 2009-01-13</p><p><b>lastReviewDate</b>: 2023-02-02</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Source <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#citation-source)</span></p><p><b>classifier</b>: MEDLINE <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MEDLINE Citation Owner <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#medline-owner)</span></p><p><b>classifier</b>: National Library of Medicine, Index Section <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#owner_value#NLM)</span></p></blockquote><p><b>currentState</b>: Medline Citation Status of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#medline-medline)</span>, PubMed PublicationStatus of ppublish <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-publication-status-ppublish)</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Pubmed <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-pubmed)</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-medline)</span></p><p><b>period</b>: ?? --> 2009-01-14 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Entrez <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-entrez)</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: id: 19029421, id: PMC3864402, id: 10.1200/JCO.2007.15.9830, pii: JCO.2007.15.9830</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>Primary title <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-title-type.html">Title Type</a>#primary)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td><td>Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.
**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.
**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.
**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.</td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17237035/">https://pubmed.ncbi.nlm.nih.gov/17237035/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 17237035</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/7679039/">https://pubmed.ncbi.nlm.nih.gov/7679039/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 7679039</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11027418/">https://pubmed.ncbi.nlm.nih.gov/11027418/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 11027418</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9815636/">https://pubmed.ncbi.nlm.nih.gov/9815636/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 9815636</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10561202/">https://pubmed.ncbi.nlm.nih.gov/10561202/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 10561202</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11134194/">https://pubmed.ncbi.nlm.nih.gov/11134194/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 11134194</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/12610188/">https://pubmed.ncbi.nlm.nih.gov/12610188/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 12610188</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470214/">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 15470214</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470213/">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 15470213</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/6337697/">https://pubmed.ncbi.nlm.nih.gov/6337697/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 6337697</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/3523938/">https://pubmed.ncbi.nlm.nih.gov/3523938/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 3523938</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/2213104/">https://pubmed.ncbi.nlm.nih.gov/2213104/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 2213104</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9267791/">https://pubmed.ncbi.nlm.nih.gov/9267791/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 9267791</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9123707/">https://pubmed.ncbi.nlm.nih.gov/9123707/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 9123707</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9619712/">https://pubmed.ncbi.nlm.nih.gov/9619712/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 9619712</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10472324/">https://pubmed.ncbi.nlm.nih.gov/10472324/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 10472324</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10524892/">https://pubmed.ncbi.nlm.nih.gov/10524892/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 10524892</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11256836/">https://pubmed.ncbi.nlm.nih.gov/11256836/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 11256836</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/14706014/">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 14706014</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>citation</b>: Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16921051/">https://pubmed.ncbi.nlm.nih.gov/16921051/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 16921051</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16170163/">https://pubmed.ncbi.nlm.nih.gov/16170163/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 16170163</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10694556/">https://pubmed.ncbi.nlm.nih.gov/10694556/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 10694556</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18207190/">https://pubmed.ncbi.nlm.nih.gov/18207190/</a></td></tr></table><p><b>resourceReference</b>: <span>id: 18207190</span></p></blockquote><blockquote><p><b>publicationForm</b></p><h3>PublishedIns</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Identifier</b></td><td><b>Title</b></td><td><b>PublisherLocation</b></td></tr><tr><td style="display: none">*</td><td>Periodical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-published-in-type.html">Published In Type</a>#D020492)</span></td><td>Electronic ISSN Type: 1527-7755, ISOAbbreviation: J Clin Oncol, ISSN Linking: 0732-183X, Medline Title Abbreviation: J Clin Oncol, NLM Unique ID: 8309333</td><td>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</td><td>United States</td></tr></table><p><b>citedMedium</b>: Internet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet)</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 36</p><p><b>articleDate</b>: 2008-12-20</p><p><b>publicationDateText</b>: 2008-Dec-20</p><p><b>language</b>: English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.3.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></p><p><b>pageString</b>: 5936-42</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: Internet without issue <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet-without-issue)</span></p><p><b>articleDate</b>: 2008-11-24</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: Abstract <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#abstract)</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/19029421/">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: DOI Based <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#doi-based)</span></p><p><b>url</b>: <a href="https://doi.org/10.1200/JCO.2007.15.9830">https://doi.org/10.1200/JCO.2007.15.9830</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publishing Model <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publishing-model)</span></p><p><b>classifier</b>: Print Electronic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#Print-Electronic)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Chemical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#chemical)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span>, Antibiotics, Antineoplastic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000903)</span>, Antineoplastic Agents, Alkylating <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018906)</span>, Antineoplastic Agents, Phytogenic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000972)</span>, Estramustine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#35LT29625A; #D004961)</span>, Vinblastine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#5V9KLZ54CY; #D014747)</span>, Doxorubicin <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#80168379AG; #D004317)</span>, Ketoconazole <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#R9400W927I; #D007654)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MeSH Heading <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading)</span></p><p><b>artifactAssessment</b>: <a name="meshHeading0"> </a></p><blockquote><p/><p><a name="meshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Adult <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000328)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged, 80 and over <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000369)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antibiotics, Antineoplastic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000903)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Alkylating <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018906)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Phytogenic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000972)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Doxorubicin <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D004317)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Estramustine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D004961)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Ketoconazole <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D007654)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoplasm Metastasis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D009362)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: mortality <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Vinblastine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D014747)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publication Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publication-type)</span></p><p><b>classifier</b>: Clinical Trial, Phase III <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D017428)</span>, Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016428)</span>, Randomized Controlled Trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016449)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Knowledge Artifact Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#knowledge-artifact-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>artifactAssessment</b>: <span>: Classifier added by Computable Publishing LLC</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Subset <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#citation-subset)</span></p><p><b>classifier</b>: IM <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#citationsubset#IM)</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author0"> </a></p><blockquote><p/><p><a name="author0"> </a></p><p><b>name</b>: Randall E Millikan </p></blockquote><p><b>forenameInitials</b>: RE</p><p><b>affiliation</b>: <span>: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author1"> </a></p><blockquote><p/><p><a name="author1"> </a></p><p><b>name</b>: Sijin Wen </p></blockquote><p><b>forenameInitials</b>: S</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author2"> </a></p><blockquote><p/><p><a name="author2"> </a></p><p><b>name</b>: Lance C Pagliaro </p></blockquote><p><b>forenameInitials</b>: LC</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author3"> </a></p><blockquote><p/><p><a name="author3"> </a></p><p><b>name</b>: Melissa A Brown </p></blockquote><p><b>forenameInitials</b>: MA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author4"> </a></p><blockquote><p/><p><a name="author4"> </a></p><p><b>name</b>: Brenda Moomey </p></blockquote><p><b>forenameInitials</b>: B</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author5"> </a></p><blockquote><p/><p><a name="author5"> </a></p><p><b>name</b>: Kim-Anh Do </p></blockquote><p><b>forenameInitials</b>: KA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="author6"> </a></p><blockquote><p/><p><a name="author6"> </a></p><p><b>name</b>: Christopher J Logothetis </p></blockquote><p><b>forenameInitials</b>: CJ</p></blockquote></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author0</b><a name="author0"> </a></p><p><b>name</b>: Randall E Millikan </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author1</b><a name="author1"> </a></p><p><b>name</b>: Sijin Wen </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author2</b><a name="author2"> </a></p><p><b>name</b>: Lance C Pagliaro </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author3</b><a name="author3"> </a></p><p><b>name</b>: Melissa A Brown </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author4</b><a name="author4"> </a></p><p><b>name</b>: Brenda Moomey </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author5</b><a name="author5"> </a></p><p><b>name</b>: Kim-Anh Do </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author6</b><a name="author6"> </a></p><p><b>name</b>: Christopher J Logothetis </p></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #meshHeading0</b><a name="meshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Adult <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000328)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged, 80 and over <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000369)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antibiotics, Antineoplastic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000903)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Alkylating <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018906)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Agents, Phytogenic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000972)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Antineoplastic Combined Chemotherapy Protocols <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000971)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Doxorubicin <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D004317)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Estramustine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D004961)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Ketoconazole <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D007654)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoplasm Metastasis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D009362)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: mortality <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000401)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Vinblastine <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D014747)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: administration & dosage <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000008)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote></blockquote></div>
</text>
<contained>
<Practitioner>
<id value="author0"/>
<name>
<family value="Millikan"/>
<given value="Randall E"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author1"/>
<name>
<family value="Wen"/>
<given value="Sijin"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author2"/>
<name>
<family value="Pagliaro"/>
<given value="Lance C"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author3"/>
<name>
<family value="Brown"/>
<given value="Melissa A"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author4"/>
<name>
<family value="Moomey"/>
<given value="Brenda"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author5"/>
<name>
<family value="Do"/>
<given value="Kim-Anh"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author6"/>
<name>
<family value="Logothetis"/>
<given value="Christopher J"/>
</name>
</Practitioner>
</contained>
<contained>
<ArtifactAssessment>
<id value="meshHeading0"/>
<artifactReference>
<reference value="#"/>
<type value="Citation"/>
</artifactReference>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000328"/>
<display value="Adult"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000368"/>
<display value="Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000369"/>
<display value="Aged, 80 and over"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000903"/>
<display value="Antibiotics, Antineoplastic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D018906"/>
<display value="Antineoplastic Agents, Alkylating"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000972"/>
<display value="Antineoplastic Agents, Phytogenic"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000971"/>
<display value="Antineoplastic Combined Chemotherapy Protocols"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004317"/>
<display value="Doxorubicin"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004961"/>
<display value="Estramustine"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006801"/>
<display value="Humans"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007654"/>
<display value="Ketoconazole"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008297"/>
<display value="Male"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008875"/>
<display value="Middle Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D009362"/>
<display value="Neoplasm Metastasis"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D011471"/>
<display value="Prostatic Neoplasms"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000401"/>
<display value="mortality"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D014747"/>
<display value="Vinblastine"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000008"/>
<display value="administration & dosage"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
</ArtifactAssessment>
</contained>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
<valueCode value="cds"/>
</extension>
<url value="https://fevir.net/resources/Citation/179631"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179631"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19029421"/>
</identifier>
<version value="1.0.0-ballot"/>
<title
value="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
<status value="active"/>
<date value="2023-12-17T16:55:23+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<useContext>
<code>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="fevir-platform-use"/>
<display value="FEvIR Platform Use"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="medline-base"/>
<display value="Medline Base"/>
<userSelected value="false"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<approvalDate value="2009-01-13"/>
<lastReviewDate value="2023-02-02"/>
<author>
<name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
</author>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="citation-source"/>
<display value="Citation Source"/>
</coding>
</type>
<classifier>
<text value="MEDLINE"/>
</classifier>
</classification>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="medline-owner"/>
<display value="MEDLINE Citation Owner"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
<code value="NLM"/>
<display value="National Library of Medicine, Index Section"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="medline-medline"/>
<display value="Medline Citation Status of Medline"/>
</coding>
</currentState>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-publication-status-ppublish"/>
<display value="PubMed PublicationStatus of ppublish"/>
</coding>
</currentState>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pubmed"/>
<display value="PubMed Pubstatus of Pubmed"/>
</coding>
</activity>
<period>
<end value="2008-11-26T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-medline"/>
<display value="PubMed Pubstatus of Medline"/>
</coding>
</activity>
<period>
<end value="2009-01-14T09:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-entrez"/>
<display value="PubMed Pubstatus of Entrez"/>
</coding>
</activity>
<period>
<end value="2008-11-26T09:00:00.000Z"/>
</period>
</statusDate>
<citedArtifact>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19029421"/>
</identifier>
<identifier>
<system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
<value value="PMC3864402"/>
</identifier>
<identifier>
<system value="https://doi.org"/>
<value value="10.1200/JCO.2007.15.9830"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="pii"/>
</type>
<value value="JCO.2007.15.9830"/>
</identifier>
<title>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="primary"/>
<display value="Primary title"/>
</coding>
</type>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<text
value="Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
</title>
<abstract>
<text
value="**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.
**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.
**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.
**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype."/>
</abstract>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/17237035/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="17237035"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/7679039/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="7679039"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11027418/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11027418"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9815636/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9815636"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10561202/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10561202"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11134194/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11134194"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/12610188/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="12610188"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15470214/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15470214"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15470213/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15470213"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/6337697/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="6337697"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/3523938/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="3523938"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/2213104/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="2213104"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9267791/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9267791"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9123707/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9123707"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9619712/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9619712"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10472324/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10472324"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10524892/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10524892"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11256836/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11256836"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/14706014/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="14706014"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<citation
value="Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982"/>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/16921051/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="16921051"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/16170163/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="16170163"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10694556/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10694556"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008"/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18207190/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18207190"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<publicationForm>
<publishedIn>
<type>
<coding>
<system value="http://hl7.org/fhir/published-in-type"/>
<code value="D020492"/>
<display value="Periodical"/>
</coding>
</type>
<identifier>
<type>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
<code value="Electronic"/>
<display value="Electronic"/>
</coding>
<text value="Electronic ISSN Type"/>
</type>
<system value="https://portal.issn.org"/>
<value value="1527-7755"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISOAbbreviation"/>
</type>
<system
value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
<value value="J Clin Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISSN Linking"/>
</type>
<system
value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
<value value="0732-183X"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="Medline Title Abbreviation"/>
</type>
<system
value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
<value value="J Clin Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="NLM Unique ID"/>
</type>
<system
value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
<value value="8309333"/>
</identifier>
<title
value="Journal of clinical oncology : official journal of the American Society of Clinical Oncology"/>
<publisherLocation value="United States"/>
</publishedIn>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet"/>
<display value="Internet"/>
</coding>
</citedMedium>
<volume value="26"/>
<issue value="36"/>
<articleDate value="2008-12-20"/>
<publicationDateText value="2008-Dec-20"/>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<pageString value="5936-42"/>
</publicationForm>
<publicationForm>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet-without-issue"/>
<display value="Internet without issue"/>
</coding>
</citedMedium>
<articleDate value="2008-11-24"/>
</publicationForm>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="abstract"/>
<display value="Abstract"/>
</coding>
</classifier>
<url value="https://pubmed.ncbi.nlm.nih.gov/19029421/"/>
</webLocation>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="doi-based"/>
<display value="DOI Based"/>
</coding>
</classifier>
<url value="https://doi.org/10.1200/JCO.2007.15.9830"/>
</webLocation>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publishing-model"/>
<display value="Publishing Model"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="Print-Electronic"/>
<display value="Print Electronic"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="chemical"/>
<display value="Chemical"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000903"/>
<display value="Antibiotics, Antineoplastic"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D018906"/>
<display value="Antineoplastic Agents, Alkylating"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000972"/>
<display value="Antineoplastic Agents, Phytogenic"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="35LT29625A"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004961"/>
<display value="Estramustine"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="5V9KLZ54CY"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D014747"/>
<display value="Vinblastine"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="80168379AG"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D004317"/>
<display value="Doxorubicin"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="R9400W927I"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D007654"/>
<display value="Ketoconazole"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH Heading"/>
</coding>
</type>
<artifactAssessment>
<reference value="#meshHeading0"/>
<type value="ArtifactAssessment"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publication-type"/>
<display value="Publication Type"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D017428"/>
<display value="Clinical Trial, Phase III"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016449"/>
<display value="Randomized Controlled Trial"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="knowledge-artifact-type"/>
<display value="Knowledge Artifact Type"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<artifactAssessment>
<display value="Classifier added by Computable Publishing LLC"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="citation-subset"/>
<display value="Citation Subset"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
<code value="IM"/>
<display value="IM"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<contributorship>
<complete value="true"/>
<entry>
<contributor>
<reference value="#author0"/>
<type value="Practitioner"/>
<display value="Millikan RE"/>
</contributor>
<forenameInitials value="RE"/>
<affiliation>
<display
value="Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org"/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#author1"/>
<type value="Practitioner"/>
<display value="Wen S"/>
</contributor>
<forenameInitials value="S"/>
</entry>
<entry>
<contributor>
<reference value="#author2"/>
<type value="Practitioner"/>
<display value="Pagliaro LC"/>
</contributor>
<forenameInitials value="LC"/>
</entry>
<entry>
<contributor>
<reference value="#author3"/>
<type value="Practitioner"/>
<display value="Brown MA"/>
</contributor>
<forenameInitials value="MA"/>
</entry>
<entry>
<contributor>
<reference value="#author4"/>
<type value="Practitioner"/>
<display value="Moomey B"/>
</contributor>
<forenameInitials value="B"/>
</entry>
<entry>
<contributor>
<reference value="#author5"/>
<type value="Practitioner"/>
<display value="Do KA"/>
</contributor>
<forenameInitials value="KA"/>
</entry>
<entry>
<contributor>
<reference value="#author6"/>
<type value="Practitioner"/>
<display value="Logothetis CJ"/>
</contributor>
<forenameInitials value="CJ"/>
</entry>
</contributorship>
</citedArtifact>
</Citation>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2023-12-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change